Jichuan pharmaceutical pulifloxacin dispersible tablets will be on the market

In February 2014, two new varieties of pulifloxacin dispersible tablets and iron albuminosuccinate oral solution in Jichuan pharmaceutical industry were approved successively, and the marketing progress of these two products also attracted market attention The company's head said the preparations for the launch of the new product have been fully considered and are being actively promoted, but the blood tonic is still waiting for the approval of the API According to the above person in charge, it is the preparation that has been approved, and the approval of API has not yet been obtained GMP certification has been actively promoted after the approval of API "This product has a certain potential." It is understood that iron albuminosuccinate oral liquid is sold as OTC products in China Its original manufacturer is italfarmaco S.A of Spain Jichuan pharmaceutical industry is the first in China to imitate it The person in charge also introduced that Prulifloxacin is a quinolones anti infective drug, and the anti restriction order still has a certain impact on it, which is a new product with high growth potential in Jichuan pharmaceutical industry According to the public information, only Epson Pharmaceutical Co., Ltd and Jichuan Pharmaceutical Co., Ltd in Jiangsu province have Prulifloxacin dispersible tablet types in China, but there are dozens of tablet manufacturers of the drug According to an analyst focusing on Jichuan pharmaceutical, both are potentially large varieties Iron albuminosuccinate oral solution is used for the treatment of iron deficiency anemia, corresponding to the large market, and it is a potential large variety similar to Pudilan Xiaoyan oral solution, while Prulifloxacin dispersible tablet does not exclude the success of replicating rabeprazole enteric coated capsule According to the public information, the sales volume of Pudilan in Jichuan Pharmaceutical Co., Ltd exceeded 1 billion yuan last year, while rabeprazole exceeded 600 million yuan, making it the two core products of the company.